167262-68-2

Basic information

• Product Name: BOC-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID
• Synonyms: 1-BOC-4-phenylpiperidine-4-carboxylic acid;1-[[(tert-Butyl)oxy]carbonyl]-4-phenyl-4-piperidinecarboxylic acid;1,4-Piperidinedicarboxylicacid, 4-phenyl-, 1-(1,1-dimethylethyl) ester;Boc-4-phenylpiperidine-4-carboxylic acid≥ 99% (HPLC);BOC-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID;1-(TERT-BUTOXYCARBONYL)-4-PHENYL-4-PIPERIDINECARBOXYLIC ACID;4-PHENYL-PIPERIDINE-1,4-DICARBOXYLIC ACID MONO-TERT-BUTYL ESTER;RARECHEM EM WB 0182
• CAS NO: 167262-68-2
• Molecular Formula: C₁₇H₂₃NO₄
• Molecular Weight: 305.37
• Product Categories: pharmacetical
• Mol File: 167262-68-2.mol
• Article Data: 23

Chemical Properties

• Melting Point: 187-189°C
• Boiling Point: 450 °C at 760 mmHg
• Flash Point: 226 °C
• Appearance: /
• Density: 1.176
• Vapor Pressure: 6.93E-09mmHg at 25°C
• Storage Temp.: Store at 0-5°C
• CAS DataBase Reference: BOC-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID(167262-68-2)
• EPA Substance Registry System: BOC-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID(167262-68-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 167262-68-2(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C17H23NO4/c1-16(2,3)22-15(21)18-11-9-17(10-12-18,14(19)20)13-7-5-4-6-8-13/h4-8H,9-12H2,1-3H3,(H,19,20)/p-1

Upstream product

• 158144-80-0 1-Boc-4-phenyl-4-piperidinecarbaldehyde 
• 3627-45-0 4-phenyl-piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 53484-76-7 4-phenylpiperidine-4-carboxylic acid hydrochloride 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 584-08-7 potassium carbonate 

Downstream Products

• 214848-11-0 4-(morpholin-4-ylcarbonyl)-4-phenyl-1-piperidinecarboxylic acid tert-butyl ester 
• 209667-67-4 1-t-butoxycarbonyl-4-phenyl-4-((4-carboethoxymethylpiperazin-1-yl)carboxamido)piperidine 
• 167262-47-7 1-tert-butyloxycarbonyl-4-phenyl-piperidine-4-carboxylic acid methyl ester 
• 954124-19-7 (S)-4-(1-(3-bromo-5-(trifluoromethyl)phenyl)ethyl) 1-tert-butyl 4-phenylpiperidine-1,4-dicarboxylate 
• 954124-26-6 (R)-4-(1-(3-bromo-5-(trifluoromethyl)phenyl)ethyl) 1-tert-butyl 4-phenylpiperidine-1,4-dicarboxylate 
• 158144-85-5 1-t-butoxycarbonyl-4-phenyl-4-hydroxymethyl piperidine 
• 312637-48-2 (S)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (S)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(S)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 312637-48-2 (R)-1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(S)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-amide 
• 475095-00-2 [1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 475094-99-6 [1-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester 
• 852319-26-7 2-amino-3-(4-chlorophenyl)-1-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-propan-1-one 
• 312639-10-4 (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine 

Relevant articles and documents

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, 10h exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.